Regadenoson

{{Drugbox | Verifiedfields = changed | verifiedrevid = 413312613 | IUPAC_name = 2-{4-[(methylamino)carbonyl]- 1H-pyrazol-1-yl}adenosine | image = Regadenoson2.png | width = 300

| tradename = | Drugs.com = Multum Consumer Information | licence_US = Regadenoson | pregnancy_AU = | pregnancy_US = C | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | routes_of_administration = Intravenous

| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =

| CAS_number_Ref =  ^Y | CAS_number = 313348-27-5 | CAS_supplemental = 875148-45-1 | ATC_prefix = C01 | ATC_suffix = EB21 | ATC_supplemental = | PubChem = 219024 | DrugBank_Ref =  ^Y | DrugBank = | UNII_Ref =  ^N | UNII = 7AXV542LZ4 | KEGG_Ref =  ^Y | KEGG = D05711 | ChEMBL_Ref =  ^N | ChEMBL = 1201750

| chemical_formula = | C=15 | H=18 | N=8 | O=5 | molecular_weight = 390.354 g/mol | synonyms = 1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]- N-methylpyrazole-4-carboxamide }}

WikiDoc Resources for Regadenoson
Articles
Most recent articles on Regadenoson Most cited articles on Regadenoson Review articles on Regadenoson Articles on Regadenoson in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Regadenoson Images of Regadenoson Photos of Regadenoson Podcasts & MP3s on Regadenoson Videos on Regadenoson
Evidence Based Medicine
Cochrane Collaboration on Regadenoson Bandolier on Regadenoson TRIP on Regadenoson
Clinical Trials
Ongoing Trials on Regadenoson at Clinical Trials.gov Trial results on Regadenoson Clinical Trials on Regadenoson at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Regadenoson NICE Guidance on Regadenoson NHS PRODIGY Guidance FDA on Regadenoson CDC on Regadenoson
Books
Books on Regadenoson
News
Regadenoson in the news Be alerted to news on Regadenoson News trends on Regadenoson
Commentary
Blogs on Regadenoson
Definitions
Definitions of Regadenoson
Patient Resources / Community
Patient resources on Regadenoson Discussion groups on Regadenoson Patient Handouts on Regadenoson Directions to Hospitals Treating Regadenoson Risk calculators and risk factors for Regadenoson
Healthcare Provider Resources
Symptoms of Regadenoson Causes & Risk Factors for Regadenoson Diagnostic studies for Regadenoson Treatment of Regadenoson
Continuing Medical Education (CME)
CME Programs on Regadenoson
International
Regadenoson en Espanol Regadenoson en Francais
Business
Regadenoson in the Marketplace Patents on Regadenoson
Experimental / Informatics
List of terms related to Regadenoson

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Regadenoson (INN, code named CVT-3146) is an A_2A adenosine receptor agonist that is a coronary vasodilator. It produces maximal hyperemia quickly and maintains it for an optimal duration that is practical for radionuclide myocardial perfusion imaging.

It was approved by the United States Food and Drug Administration on April 10, 2008 and is marketed by Astellas Pharma under the tradename Lexiscan. It has now gained approval in the European Union and is being sold under the name of Rapiscan. It is currently being marketed by GE Healthcare and is being sold in both the United Kingdom and Germany.

Regadenoson has a 2- to 3-minute biological half-life, as compared with adenosine's 30-second half-life. Regadenoson stress protocols using a single bolus have been developed, obviating the need for an intravenous line. Regadenoson stress tests are not affected by the presence of beta blockers, as regadenoson vasodilates but does not stimulate beta adrenergic receptors.